Inflammation-Dependent Association of Lipoprotein (a) with Cardiovascular and Cancer Mortality
Yiwen Zhang,Wei Wang,Lili Xu,Zhexun Lian,Jiale Huang,Yaowei Chang,Junjie Guo,Yangang Wang,Kexiu Song,Hongwei Ji
DOI: https://doi.org/10.2147/clep.s437456
2024-01-10
Clinical Epidemiology
Abstract:Yiwen Zhang, 1 Wei Wang, 2, &ast Lili Xu, 1 Zhexun Lian, 3 Jiale Huang, 4 Yaowei Chang, 5 Junjie Guo, 3 Yangang Wang, 1, &ast Kexiu Song, 6 Hongwei Ji 7, 8, &ast 1 Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 2 Department of Hematology, Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 3 Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 4 Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; 5 Department of Cardiology, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China; 6 Department of International Medicine, Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 7 Tsinghua Medicine, Tsinghua University, Beijing, People's Republic of China; 8 Department of Internal Medicine, Beijing Tsinghua Changgung Hospital, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yangang Wang, Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China, Email Hongwei Ji, Tsinghua Medicine, Tsinghua University, Beijing, People's Republic of China, Email Cardiovascular disease (CVD) and cancer rank as the two leading causes of death worldwide. Emerging evidence has suggested common mechanisms between CVD and cancer, 1 such as oxidative stress and inflammation, which not only mediate the process of atherosclerosis but also promote carcinogenesis and tumor growth. 1 Lipoprotein(a) [Lp(a)], an oxidation-specific biomarker, 2 has been associated with CVD and cancer. Inflammation may amplify the Lp(a)-associated CVD risk. 3 It is likely that inflammation may also enhance Lp(a)-associated cancer risk. If true, it will provide new insights into dual risk of cancer and CVD events, and it may also advance our understanding of collaborative management of CVD and cancer. We therefore sought to examine the association of Lp(a) with CVD and cancer deaths in participants with lower versus higher inflammation levels in a nationally representative cohort. We performed a secondary analysis by using data from the Third National Health and Nutrition Examination Survey (NHANES III), which was conducted from 1988 to 1994 by the National Center for Health Statistics (NCHS), a part of the Centers for Disease Control and Prevention (CDC). All the data are collected and disseminated by the NCHS staff. Further details about NHANES were introduced in the Supplementary Materials . Each participant, as previously described elsewhere, 4 completed a personal interview and underwent a physical examination at the mobile examination center. Serum C-reactive protein (CRP), Lp(a) and other biomarkers were assessed as previously reported. 4 A link between NHANES personal identifiers and death certificates from the National Death Index was used for assessing participants' vital status until 31 December 2019. Of all 31,311 participants underwent examinations of NHANES III, we excluded individuals with incomplete information on covariates or follow-up (N=15,363), who were not fasting or had triglycerides over 400 mg/dL (N=1259) and who had missing data on Lp(a) (N=7886). The final sample includes 6803 individuals ( Supplementary Figure 1 ). Lp(a) was log-transformed and standardized before modelling. A median value of CRP (ie, 0.21 mg/dL) was used as a cutoff point to define systemic inflammation status. We related Lp(a) levels with CVD and cancer mortality using multivariable-adjusted Cox proportional hazards models adjusted for risk factors including age, sex, race, body mass index, history of CVD, history of cancer, current smoking, hypertension, diabetes mellitus, high-density lipoprotein cholesterol level, total cholesterol level, cholesterol-lowering therapy, hypoglycemic medication, and family income. We used R version 4.2.1 for all analyses and the results were expressed as hazard ratios (HRs) and 95% confidence interval (95% CI). In this study sample (N = 6803, 56.7% females, mean age 46.3±19.4 years), over a median follow-up of 25.8 years, we documented 908 CVD deaths and 552 cancer deaths. As shown in Table 1, Lp(a) was associated with both CVD mortality (HR, 1.09; 95% CI, 1.02–1.17) and cancer mortality (HR, 1.12; 95% CI, 1.02–1.23). In participants with CRP>0.21 mg/dL, per SD increase in log-transformed Lp(a) was associated with 14% (HR, 1.14; 95% CI, 1.03–1.26) and 16% (H -Abstract Truncated-
public, environmental & occupational health